Survival of the fittest glia

Survival of the fittest glia
  • News & Views
  • Published:

Regenerative medicine

Nature Biotechnology

(2023)Cite this article

Subjects

Human glial progenitors transplanted into a chimeric mouse brain replace sick or older human glia, a finding that could one day lead to new treatments for neurological disease.

Neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s mainly affect the behavior of neurons, but in many cases they are accompanied by defects in the functioning of glial cells1. In a study in Nature Biotechnology, Vieira et al. propose an intriguing cell-based strategy for correcting glial pathology2. Using mice with a humanized glial system, the authors show that newly transplanted human glial progenitor cells (GPCs) can outcompete and replace human glial cells affected either by a Huntington’s disease genotype or by aging. Although much future research will be needed, these results raise the tantalizing possibility of glial cell replacement for the treatment of Huntington’s disease, aging and possibly other neurodegenerative diseases.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

£14.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

£139.00 per year

only £11.58 per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Young glial progenitor cells (GPCs) can outcompete and replace older and diseased GPCs.

References

  1. Valori, C. F., Possenti, A., Brambilla, L. & Rossi, D. Cells 10, 2019 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  2. Vieira, R. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01798-5 (2023).

    Article 
    PubMed 

    Google Scholar
     

  3. Allen, N. J. & Lyons, D. A. Science 362, 181–185 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  4. Osorio, M. J. et al. Glia 71, 524–540 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  5. Han, X. et al. Cell Stem Cell 12, 342–353 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  6. Benraiss, A. et al. Nat. Commun. 7, 11758 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  7. Das, M. M. & Svendsen, C. N. Aging (Albany NY) 36, 1130–1139 (2015).

    CAS 

    Google Scholar
     

  8. Das, M. M. et al. Exp. Neurol. 280, 41–49 (2016).

    Article 
    PubMed 

    Google Scholar
     

  9. Baloh, R. H. et al. Nat. Med. 28, 1813–1822 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  10. Vera, E., Bosco, N. & Studer, L. Cell Rep. 17, 1184–1192 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  11. Sorrells, S. F. et al. Nature 555, 377–381 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  12. Boldrini, M. et al. Cell Stem Cell 22, 589–599.e5 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

Download references

Author information

Authors and Affiliations

  1. Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    V. Alexandra Moser & Clive N. Svendsen

Corresponding author

Correspondence to
Clive N. Svendsen.

Ethics declarations

Competing interests

The authors declare no competing interests.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moser, V.A., Svendsen, C.N. Survival of the fittest glia.
Nat Biotechnol (2023). https://doi.org/10.1038/s41587-023-01944-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41587-023-01944-z

Associated Content

Read More

Share:

Leave a Reply

Your email address will not be published. Required fields are marked *